| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RIPK4 |
| Uniprot No | P57078 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-784 aa |
| 活性数据 | MEGDGGTPWALALLRTFDAGEFTGWEKVGSGGFGQVYKVRHVHWKTWLAIKCSPSLHVDDRERMELLEEAKKMEMAKFRYILPVYGICREPVGLVMEYMETGSLEKLLASEPLPWDLRFRIIHETAVGMNFLHCMAPPLLHLDLKPANILLDAHYHVKISDFGLAKCNGLSHSHDLSMDGLFGTIAYLPPERIREKSRLSDTKHDVYSFAIVIWGVLTQKKPFADEKNILHIMVKVVKGHRPELPPVCRARPRACSHLIRLMQRCWQGDPRVRPTFQEITSETEDLCEKPDDEVKETAHDLDVKSPPEPRSEVVPARLKRASAPTFDNDYSLSELLSQLDSGVSQAVEGPEELSRSSSESKLPSSGSGKRLSGVSSVDSAFSSRGSLSLSFEREPSTSDLGTTDVQKKKLVDAIVSGDTSKLMKILQPQDVDLALDSGASLLHLAVEAGQEECAKWLLLNNANPNLSNRRGSTPLHMAVERRVRGVVERLLARKISVNAKDEDQWTALHFAAQNGDESSTRLLLEKNASVNEVDFEGLTPMHVACQHGQENIVRILLRRGVDVSLQGKDAWLPLHYAAWQGHLPIVKLLAKQPGVSVNAQTLDGRTPLHLAAQRGHYRVARILIDLCSDVNVCSLLAQTPLHVAAETGHTSTARLLLHRGAGKEAVTSDGYTALHLAARNGHLATVKLLVEEKADVLARGPLNQTALHLAAAHGHSEVVEELVSADVIDLFDEQGLSALHLAAQGRHAQTVETLLRHGAHINLQSLKFQGGHGPAATLLRRSKT |
| 分子量 | 112.7 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人RIPK4蛋白的参考文献示例(注：以下内容为虚拟构建，仅供参考，实际文献请通过学术数据库检索)：
1. **标题**: *"Recombinant RIPK4 kinase activity mediates NF-κB signaling in epithelial development"*
**作者**: Zhang, L., et al.
**摘要**: 研究通过表达和纯化重组人RIPK4蛋白，揭示其激酶活性在激活NF-κB信号通路中的作用，并证明其在表皮细胞分化和胚胎发育中的关键功能。突变实验表明激酶结构域的特定氨基酸残基是功能必需的。
2. **标题**: *"Structural insights into RIPK4 activation loop dynamics using recombinant protein crystallography"*
**作者**: Patel, S., et al.
**摘要**: 报道了重组人RIPK4激酶结构域的高分辨率晶体结构，阐明了其激活环的构象变化对酶活性的调控机制。研究通过体外激酶实验验证了磷酸化位点对底物识别的贡献。
3. **标题**: *"RIPK4 mutations impair keratinocyte differentiation via dysregulated Wnt signaling: Evidence from recombinant rescue models"*
**作者**: Chen, Y., et al.
**摘要**: 利用重组野生型和突变型RIPK4蛋白，在角质形成细胞模型中证明RIPK4通过调控Wnt/β-catenin通路影响细胞分化。突变体的功能丧失导致表皮屏障缺陷，与先天性皮肤疾病相关。
4. **标题**: *"Recombinant RIPK4 as a therapeutic target in squamous cell carcinoma"*
**作者**: Kim, H., et al.
**摘要**: 研究显示重组RIPK4蛋白在体外促进肿瘤细胞侵袭，并通过激酶抑制剂筛选鉴定出潜在小分子化合物，可抑制其活性并减缓鳞状细胞癌的生长，提示其作为治疗靶点的潜力。
**建议**：如需真实文献，可访问PubMed或Web of Science，以“RIPK4 recombinant protein”或“RIPK4 kinase activity”为关键词检索近年研究。
**Recombinant human RIPK4 (receptor-interacting serine/threonine-protein kinase 4)** is a key regulatory protein involved in cellular signaling pathways, particularly those governing apoptosis, inflammation, and epithelial development. Belonging to the RIP kinase family, RIPK4 contains an N-terminal kinase domain and a C-terminal intermediate domain, enabling interactions with other signaling molecules. It plays a critical role in keratinocyte differentiation and skin barrier formation by modulating pathways like PKC (protein kinase C) and Wnt/β-catenin.
Mutations in the *RIPK4* gene are linked to autosomal recessive disorders such as Bartsocas-Papas syndrome, characterized by severe craniofacial malformations, syndactyly, and embryonic lethality, underscoring its importance in developmental processes. RIPK4 also interacts with IRF6 (interferon regulatory factor 6), a protein essential for palate and skin development, highlighting its role in epithelial tissue homeostasis.
In cancer research, RIPK4 exhibits dual roles: it may promote tumor progression via NF-κB activation in certain cancers (e.g., ovarian, cervical) or act as a tumor suppressor in others (e.g., hepatocellular carcinoma), depending on cellular context. Recombinant RIPK4 is widely used in biochemical studies to dissect its kinase activity, substrate specificity, and interaction networks. Its therapeutic potential is being explored in inflammatory diseases and oncology, though targeting RIPK4 requires careful modulation due to its pleiotropic effects. Ongoing research aims to clarify its context-dependent mechanisms and clinical applications.
×
